KSI-101 has been well-tolerated KSI-101 2.5 mg (n=13) KSI-101 5 mg (n=14) KSI-101 10 mg (n=14) All KSI-101 (N=41) Asia KSI-101 pooled (N=13) Summary of AEs in the Study eye, n (%) Subjects with ≥1 AEs 2 (15.4) 3 (21.4) 2 (14.3) 7 (17.1) 3 (23.1) Treatment-related AEs 1 (7.7) a 1 (7.1) b 0 2 (4.9) 0 Serious AEs 0 0 0 0 0 Treatment-related serious AEs 0 0 0 0 0 Severe AEs 0 0 0 0 0 AEs leading to study discontinuation 0 1 (7.1) b 0 1 (2.4) 0 Selected AEs in the Study Eye, n (%) Intraocular inflammation (recurrent uveitis flare-up) 1 (7.7) a 1 (7.1) b 0 2 (4.9) 0 Occlusive retinal vasculitis 0 0 0 0 0 Cataract 0 0 0 0 0 Elevated IOP 0 0 0 0 0 Eye pain 1 (7.7) a 0 0 1 (2.4) 0 Vitreous hemorrhage 1 (7.7) a 0 0 1 (2.4) 0 Final results from the APEX Study in MESI. AE, Adverse event; IOP, intraocular pressure. Events are investigator reported. Adverse events are treatment-emergent events with start date ≥first study drug date and ≤last study drug date + 28 days. a Same patient. Vitreous hemorrhage secondary to aqueous humor sampling at the Day 1 visit (pre-dose). The patient had 3+ AC cells and flare and 2+ vitreous haze prior to the Day 1 KSI-101 dose. The patient safely received all 4 doses of KSI-101 and is +26 letters in BCVA at their last visit and no intraocular inflammation. b Same patient. Uveitis flare-up consistent with underlying disease. 51